

NCI Clinical Trials Innovation Unit (CTIU)



Michael Morris, MD
Sheila A. Prindiville, MD, MPH
CTAC Meeting, July 19th, 2023

Current State of Cancer Clinical Trials

- Complex and expensive
- Burdensome designs
- Data collection often in excess of what is used
- Slow and cumbersome activation process
- Delayed results to patients and providers
- Inequitable access to studies
- *Resulting in a model that is unsustainable*

NCI Strategic Vision for Clinical Trials: 2030 and Beyond

Develop **flexible, faster, simpler, less expensive, high-impact** clinical trials that seamlessly integrate with clinical practice

Streamline processes
for trial design and
execution

Focus on essential
endpoints

Decrease regulatory
hurdles and broaden
trial access

Increase efficiency of
data collection

CTAC Strategic Planning Working Group 2020 report:
<https://deainfo.nci.nih.gov/advisory/ctac/1120/SPWGreport.pdf>

Clinical Trials Innovation Unit (CTIU): A new initiative aligned with the NCI Strategic Vision

Aims to **radically transform** how clinical trials are conducted:

- Rapidly identify and test the most innovative approaches
- Preserve current infrastructure and trials already underway

CTIU: Overarching Goals



Rapidly design and activate trials that focus on innovative science, designs, data analysis, and collaborations



Promote equitable clinical trials participation



Complement the National Cancer Plan and Cancer Moonshot's goals to work with partners in government, industry, advocacy, and other organizations to modernize trials to bring results to patients faster

CTIU: An Interagency Platform

Provides a forum for NCI, FDA, and the extramural cancer clinical research community to advance clinical care and equitable clinical trials participation through innovative:

- Science,
- Trial designs, and
- Operational efficiencies

...for a few high priority clinical research studies

CTIU: Needed Expertise at the Same Table





Co-Directors/Facilitators: Michael Morris, Sheila Prindiville

Coordinator: Iris Castro

CTIU: Collaboration from the first inception of ideas

Reservoirs of Ideas



Multidisciplinary Expertise



What Studies are Appropriate for CTIU? What is Innovative?

- Studies that “break the mold”
 - **Interventions** that non-incrementally alter standards of care
 - **Biomarkers** that will dramatically shorten trial endpoints (e.g., imaging, path, serum)
 - **Data extraction** and management that streamline trial conduct
 - **Collaborations** that conjoin expertise and resources
 - Built in: Novel evaluation, approval, and activation

CTIU: Collaboration from the first inception of ideas

Streamlined Clinical Trials: Real or Aspirational?

Pragmatica-Lung Study (S2302)

Designed to:

- **Eliminate potential barriers** to enrollment
 - **Increase diversity and enrollment** in clinical trials
 - **Streamline processes** for trial design and execution
 - **Use focused endpoints and efficient data collection**
- **No protocol required disease assessments (CT, imaging)**
 - **No protocol required lab tests**
 - **No specimen collection**
 - **Only report all Grade 5 and Unexpected Reportable Gr 3-4 AE**



Purpose: Evaluate whether ramucirumab + pembrolizumab combination therapy improves overall survival over standard treatment in people with advanced NSCLC.


CTIU's Submission Process: Focused proposals with rapid turnaround

1-2 page submission by investigator (up to 4 per group)

Rapid vetting by CTIU of ideas

Selection of proposal to advance

Collaborative protocol development with execution in NCI networks



CTIU's first round of submissions:

- ✓ • **Interventions** that non-incrementally alter standards of care using simplified designs and pragmatic approaches
- ✓ • **Biomarkers** that will dramatically shorten trial endpoints (imaging, path, serum)
- **Data extraction** and management that streamline trial conduct
- ✓ • **Collaborations** that conjoin expertise and resources
- ✓ • **Process:** Novel evaluation, approval, and activation
 - Rapid evaluation period
 - 2 weeks from submission to multiagency discussion of the proposals
 - Now preparing for final selection

CTIU progress to date


| Event | Time |
|-------------------------------------|---------------|
| Inception | February 2023 |
| Communication to NCTN investigators | May 2023 |
| Submission of proposals | June 12, 2023 |
| Evaluation of proposals | June 26, 2023 |
| Notification of investigators | June 29, 2023 |
| Selection of proposal(s) | July 2023 |

Clinical Trials Innovation Unit (CTIU) Summary

The CTIU will:

- **Select a few high-priority studies** for innovative study designs and operational procedures
- **Simplify and speed clinical testing to deliver new approaches** for diagnosis, treatment, and prevention of cancer
- **Solve problems** that face clinical trials with *innovative, inclusive, collaborative, and efficient solutions*

A collaboration between NCI, the FDA Oncology Center of Excellence, and the Extramural Community



With Appreciation

- Dr. Monica Bertagnolli
- NCI Colleagues
- FDA Oncology Center of Excellence
- Extramural partners

Questions? NCIClinicalTrialsInnovationUnit@nih.gov



NATIONAL
CANCER
INSTITUTE